What will be the role of the Fund, if anything

The antibiotic-resistant fund has many investors, including Pfizer, Novo, Teva, J&J, Takeda, Merck, Leo, Lundbeck, UCB, Lilly, Roche, Novartis, Bayer, GSK, Amgen, etc. Most of them perhaps would like to get PBT2. With this big number of companies, it could be easy to raise more money for the fund to get enough for a deal with ATH and so each company in the fund could get their share of PBT2 each company needs and pay the royalties to ATH.
This kind of deal would be rare if at all possible.
ATH would benefit because the sales of PBT2 would grow much more rapidly when there are many companies selling the product all over the world and where the problem is biggest.

To me, it has been clear that the 1 billion the Fund has is not enough for a PBT2 deal. But the companies needing PBT2 and do not want to lose their market for antibiotics investing more money in the fund could be a solution.

As you know, the Fund has stopped to do any info postings since the 4th of April. IMO, they are negotiating with ATH.